ArriVent BioPharma, Inc. (AVBP)

NGM – Цена в реальном времени. Валюта: USD

28.97

-0.05 (-0.17%)

При закрытии: May 12, 2026, 4:00 PM EDT

28.97

0.00 (0.00%)

После закрытия: May 12, 2026, 4:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

ArriVent BioPharma, Inc. (AVBP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Видео

No Data

Пресс-релизы

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Search stocks

ArriVent BioPharma, Inc. (AVBP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Видео

No Data

Пресс-релизы

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer